Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
02179 RECBIO-B
24.350-0.150-0.61%
Closed
02/08 16:08 CCT
High
24.500
Open
24.350
Turnover
4.70M
Low
23.850
Pre Close
24.500
Volume
194.00K
Price Forecast
News
Comment
Jiangsu Recbio Receives Positive Results for Phase II Study of COVID-19 Vaccine in the Philippines
12:38 AM EST, 12/27/2022 (MT Newswires) -- Jiangsu Recbio Technology (HKG:2179) received positive results for the Phase II study of its COVID-19 vaccine, ReCOV, in the Philippines, according to a fili
Philippine Drug Regulator Approves Jiangsu Recbio's Clinical Trial for Shingles Vaccine; Shares Slip 8%
02:47 AM EST, 12/19/2022 (MT Newswires) -- The Food and Drug Administration of the Philippines approved Jiangsu Recbio Technology's (HKG:2179) clinical trial for novel adjuvanted recombinant shingles
Jiangsu Recbio Technology Sees Positive Results in Phase 2 Study of COVID Booster Vaccine Among Filipinos
03:43 AM EST, 12/14/2022 (MT Newswires) -- Jiangsu Recbio Technology (HKG:2179) saw positive results from phase 2 study for its ReCOV COVID-19 booster vaccine in the Philippines, a Wednesday filing sa
Hong Kong Bourse OKs Jiangsu Recbio's H Share Listing; Shares Slip 4%
12:24 AM EST, 12/06/2022 (MT Newswires) -- The Hong Kong Stock Exchange approved Jiangsu Recbio Technology's (HKG:2179) listing of 222,498,569 H shares, according to a Monday disclosure. The company h
Jiangsu Recbio Technology to Increase Manufacturing Capacity for HPV-9 Vaccines; Shares Down 3%
01:42 AM EST, 11/21/2022 (MT Newswires) -- Jiangsu Recbio Technology (HKG:2179) will increase the manufacturing capacity of its human papillomavirus vaccine facility to 20 million doses, a Friday fili
Recbio Completes Subject Enrollment for COVID-19 Vaccine Phase 3 Trial
Jiangsu Recbio Technology to Issue 58 Million Domestic Shares
07:46 AM EDT, 11/01/2022 (MT Newswires) -- Jiangsu Recbio Technology (HKG:2179), on Monday, proposed the issuance of up to approximately 58 million domestic shares to not more than 35 qualified domest
Mid-term report of Rike Biology-BRV 2022
Biden Signs Order to Curb China in Biotechnology Following Chip Bill
The US government is reported to introduce new regulations next month to prohibit American companies from exporting chipmaking equipment to Chinese factories that produce advanced semiconductors with sub-14 nanometer processes.
Jiangsu Recbio Technology's H1 Loss Widens
12:38 AM EDT, 08/26/2022 (MT Newswires) -- Jiangsu Recbio Technology's (HKG:2179) loss attributable to owners widened to 349.7 million yuan ($51 million) for the six months ended June 30 from 330.3 mi
Company Overview
More
Jiangsu Ruike Biotechnology Co., Ltd. (“Ricoh Biotech” or the “Company”) is an innovative vaccine company committed to developing and commercializing safer and more effective innovative vaccines to address public health needs that are far from being met.
Ricoh Biotech has high-value vaccine packages and is driven by self-developed novel adjuvant technology and protein engineering technology. Through the company's strong R&D capabilities, a powerful innovative vaccine portfolio composed of 11 vaccine candidates has been established, and coverage has been strategically expanded to include 5 of the 10 most burdensome diseases in the “Global Burden of Disease” assessed by DALYs published by the World Health Organization in 2019, and the disease fields covered by 3 of the 5 best-selling vaccine products in the world in 2020. Currently, the company's core product, REC603, a recombinant HPV nine-valent vaccine, is in phase III clinical trials.
The company has formulated a clear commercialization strategy in China and overseas with the aim of further penetrating diversified markets around the world. At the same time, the company has developed three advanced technology platforms for novel adjuvant development, protein engineering, and immune evaluation. These platforms enable companies to continuously discover and develop innovative vaccines and apply advanced technology to vaccine candidates.
The company completed Series A financing in 2019, Series B financing in 2020, and completed Series B+ financing and Series C financing in 2021, respectively.
CEO： Yong Liu
Market： Hong Kong motherboard
Listing Date： 03/31/2022
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet